Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
LONDON, Feb. 02, 2016 -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 10 February, 2016 its first quarter financial results for the period ending 31 December, 2015. GW will also host a conference call the same day at 8:00 a.m. EST (1:00 p.m. GMT). Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 28 countries outside the United States. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex® (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome and Lennox-Gastaut syndrome and which is also expected to enter Phase 3 clinical trials in the treatment of Tuberous Sclerosis Complex. GW has a deep pipeline of additional cannabinoid product candidates which includes Sativex in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer, as well as compounds in Phase 1 and 2 trials for glioma, type 2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com.
Enquiries:
| GW Pharmaceuticals plc | (Today) +44 20 3727 1000 | ||
| Stephen Schultz, VP Investor Relations (U.S.) | 917 280 2424 / 401 500 6570 | ||
| FTI Consulting (Media Enquiries) | |||
| Ben Atwell / Simon Conway | + 44 20 3727 1000 |
